Tumor-infiltrating lymphocytes predict survival in ≥ pT2 urothelial bladder cancer. 2022

Stephan Ledderose, and Severin Rodler, and Lennert Eismann, and Georg Ledderose, and Carola Ledderose
Department of Pathology, Ludwig Maximilian University Munich, Germany. Electronic address: stephan.ledderose@med.uni-muenchen.de.

Tumor-infiltrating lymphocytes (TILs) are associated with improved survival in several types of cancers, including genitourinary cancers. However, multiple different scoring methods used to assess TILs complicate the comparison of different studies and are not always suitable for daily practice. In 2014, the International TILs Working Group (ITWG) proposed a simple and robust assessment method for a more standardized evaluation of TILs. Here, we validated this system in muscle-invasive urinary bladder cancer (MIBC). Patient history and histologic specimens from 203 patients with MIBC were retrospectively analyzed. The stromal TIL (sTIL) score was determined using the ITWG system and 3 groups were defined according to the degree of stromal lymphocytic infiltration: low (0-10%), intermediate (10-55%) and high (55-100%). Associations between sTIL score, clinicopathological variables, tumor-specific survival (TSS), overall survival (OS), and disease-free survival (DFS) were analyzed. High stromal lymphocytic infiltration was associated with significantly higher OS, TSS and DFS when compared to low grade sTILs. The survival benefit remained statistically significant in multivariate analyses, confirming that sTILs are a strong independent positive prognostic factor in patients with MIBC. In summary, the degree of sTILs as defined by the ITWG robustly predicts survival in MIBC patients. Prospective studies with larger case numbers are needed to determine whether sTILs should be included in staging guidelines and how they could aid in therapeutic decision making.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D016246 Lymphocytes, Tumor-Infiltrating Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer. Tumor Infiltrating Lymphocyte,Tumor-Derived Activated Cell,Tumor-Derived Activated Cells,Tumor-Infiltrating Lymphocyte,Tumor-Infiltrating Lymphocytes,Activated Cell, Tumor-Derived,Activated Cells, Tumor-Derived,Infiltrating Lymphocyte, Tumor,Infiltrating Lymphocytes, Tumor,Lymphocyte, Tumor Infiltrating,Lymphocyte, Tumor-Infiltrating,Lymphocytes, Tumor Infiltrating,Tumor Derived Activated Cell,Tumor Derived Activated Cells,Tumor Infiltrating Lymphocytes

Related Publications

Stephan Ledderose, and Severin Rodler, and Lennert Eismann, and Georg Ledderose, and Carola Ledderose
August 2015, Melanoma research,
Stephan Ledderose, and Severin Rodler, and Lennert Eismann, and Georg Ledderose, and Carola Ledderose
August 2015, The Journal of urology,
Stephan Ledderose, and Severin Rodler, and Lennert Eismann, and Georg Ledderose, and Carola Ledderose
July 2019, Translational andrology and urology,
Stephan Ledderose, and Severin Rodler, and Lennert Eismann, and Georg Ledderose, and Carola Ledderose
August 2018, Pathology, research and practice,
Stephan Ledderose, and Severin Rodler, and Lennert Eismann, and Georg Ledderose, and Carola Ledderose
March 2007, Proceedings of the National Academy of Sciences of the United States of America,
Stephan Ledderose, and Severin Rodler, and Lennert Eismann, and Georg Ledderose, and Carola Ledderose
January 2024, Gynecologic oncology,
Stephan Ledderose, and Severin Rodler, and Lennert Eismann, and Georg Ledderose, and Carola Ledderose
July 2022, Journal of personalized medicine,
Stephan Ledderose, and Severin Rodler, and Lennert Eismann, and Georg Ledderose, and Carola Ledderose
December 2019, Journal of cancer research and clinical oncology,
Stephan Ledderose, and Severin Rodler, and Lennert Eismann, and Georg Ledderose, and Carola Ledderose
October 2015, Virchows Archiv : an international journal of pathology,
Stephan Ledderose, and Severin Rodler, and Lennert Eismann, and Georg Ledderose, and Carola Ledderose
January 2020, Cells,
Copied contents to your clipboard!